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Edited by Sandro SonninoAbstract The transmembrane (TM) domains in P-glycoprotein
(P-gp) contain the drug binding sites and undergo conforma-
tional changes driven by nucleotide catalysis to eﬀect transloca-
tion. However, our understanding of exactly which regions are
involved in such events remains unclear. A site-directed labelling
approach was used to attach thiol-reactive probes to cysteines
introduced into transmembrane segment 6 (TM6) in order to per-
turb function and infer involvement of speciﬁc residues in drug
binding and/or interdomain communication. Covalent attach-
ment of coumarin-maleimide at residue 339C within TM6 re-
sulted in impaired ATP hydrolysis by P-gp. The nature of the
eﬀect was to reduce the characteristic modulation of basal activ-
ity caused by transported substrates, modulators and the potent
inhibitor XR9576. Photoaﬃnity labelling of P-gp with [3H]-azi-
dopine indicated that residue 339C does not alter drug binding
per se. However, covalent modiﬁcation of this residue appears
to prevent conformational changes that lead to drug stimulation
of ATP hydrolysis.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Drug transport1. Introduction
The ‘‘multidrug’’ transporters such as P-glycoprotein (P-gp
or ABCB1) are at the heart of many serious clinical problems
including resistance to antibiotic and cancer chemotherapy.
Due to its clinical importance in cancer therapy, P-gp remains
one of the most investigated ‘‘multidrug’’ transporters, how-
ever, many fundamental aspects of its transport mechanism
have not been established. For example, a largely unexplained
characteristic of P-gp is the ability to interact with an extraor-
dinarily broad range of chemically and functionally unrelatedAbbreviations: P-gp, P-glycoprotein; MDR, multidrug resistance;
ABC, ATP Binding Cassette family; TM6, transmembrane segment
6; NBD, nucleotide binding domain; ANOVA, one-way analysis of
variance; SDS–PAGE, sodium dodecyl sulfate–polyacrylamide gel
electrophoresis; S.E.M., standard error of the mean
*Corresponding author. Fax: +44 1865 221 834.
E-mail address: richard.callaghan@ndcls.ox.ac.uk (R. Callaghan).
0014-5793/$30.00  2005 Published by Elsevier B.V. on behalf of the Feder
doi:10.1016/j.febslet.2005.06.030compounds. This characteristic of P-gp arises through the
presence of multiple, allosterically linked, but pharmacologi-
cally distinct drug binding sites on the protein [1–5]. Early
photoaﬃnity studies suggested that the binding sites comprise
elements from both halves of the protein [6,7]. Evidence ob-
tained from mutational studies [8,9], mass spectroscopy data
[10] and cysteine-scanning mutagenesis [11,12] indicates that
several TM segments are involved in the drug binding site,
with TMs 5, 6, 11 and 12 featuring prominently.
Transport from these drug binding sites is mediated in an
ATP-dependent fashion and a widely accepted model suggests
that the two nucleotide binding domains (NBDs) hydrolyse
ATP in an alternating and co-operative manner [13]. In addi-
tion, the NBDs and drug binding sites display co-operativity
during P-gp function as evidenced by the ability of drugs to
stimulate nucleotide hydrolysis. For a coupled active transport
mechanism there needs to be communication in both direc-
tions (i.e. NBDﬁ TMD and TMDﬁ NBD) to eﬀect vectorial
drug movement [14]. Unfortunately, there is a paucity of infor-
mation on the molecular regions involved in mediating com-
munication in either direction.
That there is two-way coupling with concomitant conforma-
tional changes has been established by numerous investiga-
tions, including tryptic digestion [15,16], binding of the
conformationally sensitive antibody UIC2 [17], and spectro-
scopic studies involving trypotophan ﬂuorescence quenching
or 2H/H-exchange proﬁles [18,19]. Investigations using elec-
tron microscopy of 2D crystals have conﬁrmed that function-
ally relevant structural changes accompany progression
through the catalytic cycle [20,21]. Unfortunately, none of
these techniques are at a suﬃcient resolution to identify spe-
ciﬁc regions of P-gp, or individual amino acids, that are in-
volved in mediating the conformational changes.
Recently we provided evidence that transmembrane segment
6 (TM6) undergoes distinct topographical changes in response
to stimuli emanating from the NBDs [22]. This approach,
using puriﬁed and reconstituted protein, allowed direct assign-
ment of functional alterations to P-gp, in contrast to studies of
TM6 topography in membranes containing P-gp [20]. TM6 is
of interest since it is directly linked to the N-terminal NBD in
P-gp and therefore a likely candidate for communication path-
ways. Furthermore, several mutations in TM6 caused by drug
selection altered the resistance proﬁle [23], as did directed
mutagenic investigations [24]. In the current investigation
site-directed cysteine labelling was used to provide informationation of European Biochemical Societies.
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cysteine containing P-gp isoforms were labelled covalently
with coumarin-maleimide (CM) and the eﬀect of this modiﬁca-
tion on function assessed. The results identify residue 339 in
P-gp as being involved in conformational changes required
to communicate drug binding events to the NBDs.2. Materials and methods
2.1. Materials
Coumarin-maleimide was purchased from Molecular Probes (Lei-
den, NL). Octyl-b-D-glucoside, paclitaxel and Ni–NTA His Bind
Superﬂow resin were obtained from Merck Biosciences (Nottingham,
UK). [3H]-Azidopine (59 Ci/mmol) was purchased from Amersham
Biosciences (Chalfont St. Giles, UK). Crude Escherichia coli lipid ex-
tract was obtained from Avanti Polar Lipids (Alabaster, USA). In-
sect-Xpress medium was purchased from Cambrex BioScience
(Nottingham, UK) and Excell 405 from AMS Biotechnology (Abing-
don, UK). XR9576 was a kind donation from Xenova Ltd. (Slough,
UK). All other reagents were of at least analytical grade and were from
Sigma (Poole, UK).
2.2. Production of recombinant baculovirus
Expression and characterisation of a cysteineless, histidine-tagged
P-gp in mammalian cells has been described [25,26]. Single cysteines
were introduced into the cysteineless multidrug resistance 1 coding
sequence by site-directed mutagenesis, employing the mutagenic oligo-
nucleotides (5 0–3 0; in each case the cysteine codon is in bold):
oligoV331C, TCTATTGGACAATGCCTCACTGTA; oligoT333C,
ATTGGACAAGTTCTCTGCGTATTCTTTTC; oligoF335C, CTC-
ACTGTATGCTTTTCTGTGTTAATTGGG; oligoS337C, CTGTAT-
TCTTTTGTGTGTTAATTGGG; oligoL339C, CTTTTCTGTATGC-
ATTGGGGCT; oligoG341C, CTGTATTAATTTGCGCATTTAGT-
GTTGG;oligoF343C,TTTTCTGTATTGATTGGGGCTTGTAGTG-
TTGG.
The nucleotide sequence of the mutated DNA fragments were veri-
ﬁed by DNA sequencing. The entire coding sequence for cysteineless-
P-gp and single cysteine mutants, including the 5 0 Kozak sequence,
was introduced into the baculoviral transfer vector pBacPAK9 (Clon-
tech) and recombinant baculoviruses generated by in vivo recombina-
tion with BacPAK6 (Clontech).
2.3. Expression, puriﬁcation and reconstitution of P-gp from insect cell
membranes
Trichoplusia ni (high-ﬁve) cells were infected with recombinant bac-
ulovirus and P-gp containing membranes isolated as previously
reported [22,26]. Membranes were resuspended in buﬀer (10 mM
Tris–HCl, 150 mM NaCl, 1.5 mM MgCl2, 20% glycerol, 0.4% (w/v)
lipids, 20 lM leupeptin, 1 mM benzamidine, 1 lM pepstatin, and 2%
(w/v) octyl-b-D-glucoside, pH 7.4) to solubilise protein [22,26]. Soluble
proteins were added to Ni–NTA resin at a ratio of 0.5 ml resin to
50 mg soluble protein, washed, and eluted using a stepwise gradient
of imidazole. Fractions containing P-gp were reconstituted by SM-2
BioBead mediated detergent adsorption and the eﬃciency of reconsti-
tution assessed by examination of protein and lipid migration through
sucrose density gradients as described [26]. Protein concentration was
determined by densitometric analysis of Coomassie-stained sodium dode-
cyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) gels [22].2.4. Measurement of ATP hydrolysis
ATP hydrolysis was determined using minor modiﬁcations [26] of a
colorimetric procedure [27] to measure the liberation of inorganic
phosphate (Pi). Proteoliposomes (0.3 lg P-gp) were incubated in
the presence of varying ATP concentrations (0–1.75 mM) for 20 min
at 37 C to determine the ‘‘basal’’ rate of hydrolysis. To determine
the stimulatory eﬀects of drugs, the assays were also done in the pres-
ence of 30 lM of the transported substrate vinblastine or the modula-
tor nicardipine. The ATPase activity was plotted as a function of ATP
concentration and the relationship ﬁtted, using non-linear regression,
with the Michaelis–Menten equation. Alternatively, the activity wasmeasured at constant ATP (2 mM) and varying drug concentration
(109–104 M). The relationship between activity and drug concentra-
tion was ﬁtted with the general dose–response equation [28].
2.5. Labelling of cysteine containing P-gp isoforms with CM
Samples of each puriﬁed, reconstituted P-gp isoform (1.5–3 lg)
were incubated with CM (10 lM) for various times between 0 and
300 min at 20 C in the dark. Coumarin-maleimide was added from
concentrated DMSO based stocks with solvent levels not exceeding
0.5% (v/v). The reaction was terminated with dithiothreitol (100 lM)
and the samples placed on ice. Each sample was then diluted 1:1 with
glycerol free buﬀer (150 mM NaCl, 1.5 mM MgSO4, 0.02% (w/v)
NaN3, and 20 mM Tris–HCl, pH 7.4) and subjected to ultracentrifuga-
tion (15 min, 4 C, 125000 · g) to remove unbound probe. Pellets were
resuspended in Laemmli sample buﬀer and proteins resolved using
7.5% SDS–PAGE. A further sample was incubated in 2% (w/v) SDS
to denature protein prior to incubation with CM as described above.
This sample was used to determine 100% labelling with ﬂuorophore.
Gels were analysed using the BioDocIt Imaging system (light source;
k = 302 nm) to determine labelling intensity. The latter was quantiﬁed
using densitometric analysis (NIH Image Software). Time courses for
labelling were plotted as the percent labelling (relative to denatured
sample) as a function of time and the exponential association curve
was ﬁtted using non-linear regression:
L ¼ Lmax  ð1 ektÞ; ð1Þ
where L is the percent labelled, Lmax the maximum percent labelled, t
the time (min) and k is the observed rate constant for labelling (t1/2
= ln2/k).
Following imaging, the gels were stained with Coomassie blue to en-
sure equivalent protein loading.
In order to examine the functional consequences of labelling, sam-
ples were treated in a similar fashion to above. The values for half-life
of labelling obtained were used in to ensure >90% labelling in each
preparation. The ﬁnal ultracentrifugation step to remove unbound
probe was not employed and the samples analysed, immediately fol-
lowing the labelling reaction, for ATPase activity or drug binding.
2.6. [3H]-Azidopine labelling of P-glycoprotein
Preparations of both cys-less and L339C isoforms of P-gp were la-
belled to an extent of 90% with CM as described [22]. Proteoliposomes
(0.3 lg) were then incubated in the presence of 0.6 lM [3H]-azidopine
in a total volume of 40 ll for 2 h at 20 C in the dark. Samples were
also incubated with radiolabel and an excess (100 lM) of one of the
following: vinblastine, paclitaxel, nicardipine or XR9576. Photoacti-
vated cross-linking of [3H]-azidopine to P-gp was then achieved by
irradiation with UV light for 5 min on ice (100 W, 5 cm). Laemmli
sample buﬀer was added to the samples and proteins resolved using
7.5% SDS–PAGE. Gels were ﬁxed in 25% (v/v) isopropanol, 10%
(v/v) acetic acid and washed in Amplify prior to autoradiography.
The band intensities were quantiﬁed using densitometric analysis
(NIH Image Software).
2.7. Data analysis
All non-linear regression analyses were produced using the Graph-
Pad Prism 3.0 program. A minimum data set was obtained from at
least three independent protein puriﬁcation preparations and all values
are given as means ± standard error of the mean (S.E.M). Multiple
data comparisons (>3 sets) were analysed using one-way analysis of
variance (ANOVA), with a Newman–Keul post hoc test and statistical
signiﬁcance was presumed, where P < 0.05.3. Results
3.1. Labelling of P-gp isoforms containing cysteine residues
within TM6
Single sites for mutation to cysteine within TM6 were chosen
based upon structural and topological considerations. Seven
individual amino acid substitutions at alternate positions
within TM6 were used in order to produce 360 coverage of
the a-helical face, and span the hydrophobic core of the lipid
Fig. 1. Time course for the labelling of L339C P-gp with CM. (a) Pure,
reconstituted P-gp (1.5–3 lg) was labelled with CM (10 lM) as
described for various times (lanes i–vii). Bands were detected by
ﬂuorescent imaging and quantiﬁed by densitometry as a percentage of
that determined for denatured protein incubated with CM (lane viii).
(b) The time-course of labelling L339C P-gp with CM obtained from
three independent puriﬁed protein preparations.
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introduced cysteine residues [22]. The time-course shown in
Fig. 1 was obtained for mutant L339C, although similar pro-
ﬁles were generated for each P-gp isoform. Importantly, each
individual experiment contained a sample of denatured protein
in order to quantitatively assess the extent of labelling relative
to this maximum possible extent of labelling. Residue 324C,
which lies on an accessible extracellular loop, was also exam-
ined to ensure ﬁdelity of labelling conditions. The half-lives
for reaction of introduced cysteine residues with CM varied
from 23 ± 1 min obtained for L339C to 52 ± 3 min for the
F335C isoform. The half-life for L339C was signiﬁcantly
shorter (P < 0.05) than that obtained for the other TM6
mutant isoforms. Non-speciﬁc labelling of the cysteine-free
(cys-less) control isoform at the chosen conditions was mini-
mal compared to the single cysteine isoforms.
3.2. Labelling P-gp isoform 339C alters drug stimulation of
ATPase activity
Initial eﬀorts to determine the eﬀects of CM labelling of mu-
tant TM6 isoforms on ATPase activity attempted to remove
any unbound probe by dialysis, ultracentrifugation or ultraﬁl-
tration. Each produced deleterious eﬀects on the maximal
ATPase activity (Vmax) of P-gp, as much as 75% in the case
of dialysis. This rendered the removal of non-reacted probe
from the samples impracticable and necessitated the investiga-
tion of any potential non-speciﬁc (i.e. cysteine-independent)
inﬂuence of CM on protein activity. The Vmax for ATP hydro-
lysis by cys-less P-gp was 0.58 ± 0.15 lmol Pi min1 mg1.
Incubation of this protein with 10 lM CM produced an iden-
tical activity (94 ± 5%, n = 6, NS) suggesting that CM has no
eﬀect on ATPase activity of cys-less P-gp. The basal rate ofATP hydrolysis of cys-less P-gp was stimulated 2.9 ± 0.3 fold
by 30 lM nicardipine and 2.1 ± 0.3 fold by vinblastine. Incu-
bation of cys-less P-gp with these drugs in the presence of
10 lM CM produced 15–20% reductions in the stimulated
ATPase activities, which were not statistically signiﬁcant (AN-
OVA). Therefore, the absence of non-speciﬁc eﬀects on P-gp
function justiﬁed the decision not to remove unreacted probe
from samples prior to measurement of ATP hydrolysis. How-
ever, all values of ATPase activity following reaction with CM
were expressed as a percentage of the value obtained in a con-
current experiment using the same isoform without CM.
Fig. 2 shows the eﬀects that covalent attachment of CM to
each single cysteine isoform produced on the basal ATPase
activity and the degree of stimulation produced by vinblastine
and nicardipine. Covalent modiﬁcation of the TM6 mutant
isoforms produced minor reductions in the Vmax of basal ATP-
ase activity, none of which were signiﬁcantly diﬀerent from
that observed for cys-less P-gp (Fig. 2(a)). Similarly, CM label-
ling of TM6 mutants was also unable to modulate the stimula-
tion of activity by vinblastine; with one exception (Fig. 2(b)).
The Vmax of hydrolysis in the presence of vinblastine was re-
duced to 41 ± 5% (P < 0.01) of that observed in the absence
of CM for the L339C isoform. None of the other TM6 mutant
isoforms displayed signiﬁcant alterations in the stimulation of
ATP hydrolysis by vinblastine. Full Michaelis–Menten plots
for the unlabelled and CM-modiﬁed L339C isoform of P-gp
are shown in Fig. 3. The data demonstrate that the vinblastine
mediated reduction in Vmax was not accompanied by a shift in
aﬃnity (Km(ATP)) of the CM labelled L339C (Km = 0.40 ±
0.05 mM) compared to native protein (Km=0.32 ± 0.05 mM).
Similarly, of the TM6 mutants examined, only L339C dis-
played a signiﬁcant reduction in the nicardipine stimulated
Vmax (46 ± 4%, P < 0.01) following labelling with CM (Fig.
2(c)). In the presence of nicardipine, the Km of unmodiﬁed
L339C (Km = 0.33 ± 0.03 mM) was not signiﬁcantly altered
(Km = 0.29 ± 0.05 mM) following covalent modiﬁcation with
CM (Fig. 3). Clearly, the eﬀect of labelling residue 339C with
CM causes a depression in the maximal ATPase activity, but
only in the presence of drugs.3.3. Coumarin-maleimide labelled 339C P-gp displays modiﬁed
TMDﬁ NBD coupling
To further examine the perturbed drug stimulation of ATP-
ase activity, full dose–response analyses were generated for
native and CM labelled L339C P-gp for several drugs
(Fig. 4). P-gp has previously been demonstrated to contain
at least four distinct drug-binding sites [3] and a representative
substrate for each of the sites was chosen. The data was pro-
duced using 2 mM ATP to ensure maximal hydrolytic activity
and the eﬀects were related to those observed for protein in the
absence of drug. The eﬀects of these drugs on ATPase activity
of cys-less P-gp were unaltered by the presence of CM (data
not shown). Hence, any observed eﬀects were due to attach-
ment of probe to the cysteine at position 339 in P-gp.
Stimulation by vinblastine was characterized by a 2.3 ± 0.1
fold increase in basal activity for unlabelled L339C and at a
potency of EC50 = 6.8 ± 0.5 lM (Fig. 4(a)). However, for the
CM labelled L339C P-gp vinblastine did not stimulate activity,
even at concentrations as high as 100 lM. The stimulation of
unlabelled L339C P-gp (2.3 ± 0.2 fold-basal) by nicardipine
was described with a potency of EC50 = 2.3 ± 0.4 lM
Fig. 2. The eﬀect of CM labelling at speciﬁc residues throughout TM6
on theATPase activity ofP-gp.Mutant isoformsofP-gpwere labelled at
20 C with CM as described in Section 2. Samples (0.3 lg P-gp) were
assessed using a range of ATP concentrations (0–1.75 mM) for (a) basa
ATPase activity or in the presence of (b) 30 lMvinblastine or (c) 30 lM
nicardipine. The maximal activity determined by non-linear regression
of the Michaelis–Menten equation and activity obtained for individua
isoforms in the absence of CM was assigned as 100%. All values
following incubation with CM were expressed as a percentage of this
value and represent mean ± S.E.M. obtained from at least three
independent protein preparations. \ denotes an eﬀect signiﬁcantly
diﬀerent (P < 0.05, ANOVA) from that observed for unlabelled protein
Fig. 3. The eﬀect of CM labelling of L339C on the Michaelis–Menten
parameters describing ATP hydrolysis. Pure, reconstituted P-gp
(0.3 lg) was incubated in the presence (dashed lines) or absence (solid
lines) of CM (10 lM) at 20 C for 80 min (i.e. 90% labelling). ATPase
activity was determined for varying ATP concentrations (0–1.75 mM)
in the presence of 30 lM of either nicardipine (d,s) or vinblastine
(j,h). Activity was normalized such that the Vmax obtained for
unlabelled L339C P-gp in the presence of nicardipine was 100%. The
Michaelis–Menten equation was ﬁtted to the data using non-linear
regression. Error bars represent the S.E.M. obtained from eight
independent puriﬁed protein preparations.
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.(Fig. 4(b)). In contrast to the eﬀect seen with vinblastine, the
labelled L339C isoform retained stimulation of ATP hydroly-
sis by nicardipine although the overall extent was reduced by
60% to 1.3 ± 0.1 fold-basal (P < 0.05, n = 4). However, the po-
tency of nicardipine to stimulate ATP hydrolysis (EC50 =
2.3 ± 0.2 lM) was unaﬀected by covalent attachment of CM
to residue 339C. The eﬀect of paclitaxel on ATP hydrolysis
in the CM labelled L339C isoform of P-gp was similar to that
observed for vinblastine. The ATPase activity of unlabelled
L339C-P-gp was stimulated 2.1 ± 0.1 fold by paclitaxel
(EC50 = 8.6 ± 3.7 lM) and this was abrogated following the
attachment of CM (Fig. 4(c)). Finally, the non-transported
modulator XR9576 displayed the highest potency to alter
ATP hydrolysis (IC50 = 0.08 ± 0.01 lM), however the nature
of this eﬀect was a reduction of activity to 0.40 ± 0.05 fold ba-
sal (Fig. 4(d)). Following the reaction of L339C with CM,
XR9576 retained the ability to inhibit ATP hydrolysis to a le-
vel of 0.33 ± 0.03 fold-basal. However, the potency of the inhi-
bition in native protein was reduced 12-fold to IC50 = 1.0 ±
0.3 lM (P < 0.01, n = 3).
3.4. Altered drug stimulated ATPase activity of CM labelled
L339C P-gp is not due to impaired drug binding
The eﬀect of labelling 339C on drug modulation of ATPase
activity was not identical for the four established [3] distinct
drug binding sites, with changes observed in potency or fold
stimulation. The alteration of drug stimulation of ATP hydro-
lysis may be due to either impaired binding to the TMDs, or an
altered TMDﬁ NBD communication. To address this issue,
the eﬀect of CM on the binding of a 1,4-dihydropyridine,
[3H]-azidopine, was investigated (Fig. 5). The extent of [3H]-
azidopine binding to the CM labelled L339C isoform of
P-gp was identical to unlabelled protein. However, the results
in Section 3.3 indicate that the various drug binding sites are
diﬀerentially aﬀected by 339C labelling with CM. Consequently,
the displacement of [3H]-azidopine binding was examined for
Fig. 4. Dose-dependent drug stimulation of ATP hydrolysis by native and CM labelled L339C. P-gp was incubated with CM (10 lM) at 20 C for
80 min to achieve 90% labelling. Samples (0.3 lg) were assayed for ATPase activity using 2 mM ATP and varying concentrations (109–104 M) of
(a) vinblastine, (b) nicardipine, (c) paclitaxel or (d) XR9576. Activity was expressed as a fraction of the rate observed in the absence of drug. Native
protein is shown as ﬁlled circles (d), whilst labelled L339C is depicted with open circles (s). The general dose–response equation was ﬁtted to the
data using non-linear regression and error bars represent S.E.M. from at least three independent protein preparations.
Fig. 5. [3H]-Azidopine photoaﬃnity labelling of native and CM
labelled L339C. P-gp (1.5 lg) was incubated in the presence or absence
of CM (10 lM) at 20 C for 80 min. Samples (0.3 lg) were subse-
quently incubated with 0.6 lM [3H]-azidopine for 2 h in the dark
(20 C) in the absence or presence of drugs. Samples were subjected to
UV-irradiation for 5 min, SDS–PAGE and ﬁxed for autoradiography.
(a) Autoradiograms obtained for native and unlabelled L339C in the
absence (lane i), or presence of vinblastine (ii), nicardipine (iii),
paclitaxel (iv) or XR9576 (v). All drugs were added to a ﬁnal
concentration of 100 lM. (b) Densitometric analysis of autoradio-
grams using native (j) or labelled P-gp (h), with 100% labelling
eﬃciency deﬁned as the intensity for unlabelled protein in the absence
of added drug. Error bars represent S.E.M. from at least three
independent protein preparations.
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following treatment with CM under the conditions employed
in the assay. The degree of displacement produced by
100 lM of each drug showed a small degree of variation, pre-
sumably reﬂecting individual aﬃnities. Importantly, the ability
of drugs to displace [3H]-azidopine binding was not aﬀected by
the covalent modiﬁcation of residue 339 C (Fig. 5(a)–(b)) and
was identical to the eﬀects observed in cys-less P-gp in the pres-
ence or absence of CM (data not shown).4. Discussion
A great deal of evidence has previously been presented for
the involvement of TM6 in the overall drug translocation
mechanism of P-gp, much of it obtained through measurement
of drug resistance proﬁles or total cellular accumulation of
drugs [23,24]. Two mechanistic explanations for the altered
overall P-gp activity caused by speciﬁc TM6 mutations are a
reduction in drug binding to the transporter (although this
has rarely been shown directly) or an altered communication
between the TMDs and NBDs. The present investigation sup-
ports the latter hypothesis and provides detailed evidence that
the communication pathway includes residue L339 within
TM6.
We have recently provided direct evidence that TM6 is in-
volved in these conformational changes and appears to under-
go tilting along its long axis [22]. In the current investigation
we demonstrate that the fundamental characteristics of basal
ATPase activity are insensitive to covalent attachment of
A. Rothnie et al. / FEBS Letters 579 (2005) 3984–3990 3989CM to at several positions along and around the long axis of
TM6, suggesting retention of the normal sequence of confor-
mational changes driven by nucleotide binding and hydrolysis.
However, the drug stimulation of ATP hydrolysis was signiﬁ-
cantly impaired, but only following attachment of CM to res-
idue 339. Previous cross-linking based investigations [11,12]
have ‘‘mapped’’ residue 339 within a large drug binding pocket
in P-gp. However, direct measurements of drug binding to the
protein were not undertaken in either study. Moreover, the
partial protection against MTS-verapamil by verapamil argues
against a truly competitive interaction, although residue 339C
may indeed be close to the binding site as suggested [11]. MTS-
verapamil does not behave similarly to verapamil since it
would be expected to stimulate ATPase activity, rather than
inhibit as reported [11]. Indeed vinblastine, which binds to
the same site as verapamil [31], was shown in the present
investigation to stimulate ATP hydrolysis by unmodiﬁed
339C-P-gp. More convincingly, direct and quantitative mea-
surements in the present manuscript have demonstrated that
the binding of [3H]-azidopine, was unaﬀected by the attach-
ment of CM to residue 339C in TM6. Azidopine and nicardi-
pine are both 1,4-dihydropyridines and therefore likely to
interact at an identical site on P-gp [32]. In addition, the ﬁdel-
ity of binding capacity at multiple pharmacophoric regions
within P-gp is unaﬀected by covalent attachment of CM to res-
idue 339C within TM6. This indicates that this amino acid of
P-gp is unlikely to contribute to a large drug binding
‘‘domain’’ as has been proposed [33]. Indeed, it is well established
that there are several drug binding sites on P-gp [3], although it
is less clear whether they communicate with the NBDs via a
single common, or multiple distinct, pathways. That CM label-
ling of the 339C isoform of P-gp was able to aﬀect signalling
from four pharmacologically distinct sites suggests that the
respective inﬂuences are funnelled via residue 339 in TM6.
How does drug binding aﬀect nucleotide hydrolysis, and
which event drives the conformational changes during a trans-
port cycle? These questions continue to vex researchers in the
ﬁeld and are likely to involve eﬀects at one of the following
steps: (i) ATP binding, (ii) hydrolysis of the c-phosphate, (iii)
release of inorganic phosphate or (iv) ADP dissociation.
Unfortunately, these individual steps are diﬃcult to measure
due to technical diﬃculties associated with the poor aﬃnity
of the nucleotide species for P-gp. Measurement of conforma-
tional changes in P-gp, and other ATP Binding Cassette
(ABC) proteins, consistently indicates that the driving force
is provided by the binding and hydrolysis of nucleotide
[19,34]. Transported substrates produce minor or negligible
overall conformational changes per se [16–18], supporting
the hypothesis that the catalytic cycle in P-gp is analogous to
a constantly turning waterwheel powered by nucleotide hydro-
lysis, whilst drug binding serves to accelerate or decelerate its
rate [35]. In the current manuscript it appears that residue
339 in TM6 undergoes conformational changes (or, is within
their vicinity) critical to the stimulation or inhibition of ATP
hydrolysis produced by the binding of drugs within the TMDs
(i.e. TMDﬁ NBD communication). The attachment of CM
to this residue impairs the conformational change, although
importantly, it does not perturb the fundamental changes re-
quired for basal nucleotide hydrolysis. In a recent manuscript
we have demonstrated that the reverse communication path-
way (NBDﬁ TMD) also aﬀects the region proximal to residue
339C [22]. Future investigations are aimed at identifying fur-ther amino acids within P-gp which mediate conformational
changes and to determine the local changes in protein topogra-
phy produced by drug binding.
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